The South African government says it could fill the potential gap in the number of doses it will need of the twice-yearly HIV-prevention jab to end Aids by 2043, by getting a group of local pharmaceutical companies to make generic shots from 2027 onwards. There is, however, a hitch. None of the companies that will be involved have a licence from lenacapavir’s inventor, Gilead Sciences, to make the jab.
Related Posts
News24 | Eastern Cape top brass admits ‘embarrassing’ Gqeberha Flying Squad failure
- CoreNews Africa
- September 30, 2026
- 0
The Eastern Cape police commissioner has used one word to describe what happened when Gqeberha’s Flying Squad was left without a working vehicle to respond […]
News24 | REAL POLITIKI | Who’s to blame for SA’s immigration issues?
- CoreNews Africa
- June 29, 2026
- 0
As South Africa grapples with rising tensions around immigration, we explore the factors driving the crisis, the human impact on migrants, and the government’s response.
ACSA Reassures Stakeholders, Airlines, Public That Jet Fuel Stock Levels Remain Stable
- CoreNews Africa
- August 27, 2026
- 0
Johannesburg – Airports Company South Africa (ACSA) has moved to allay fears of Jet fuel supply disruptions, saying it has instituted active stock management […]